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ABSTRACT 
Background: Nasotracheal intubation is often necessary in patients under- 
going elective or emergency maxillofacial surgery. Previous studies have sug- 
gested that the increase in blood pressure after nasotracheal intubation is sig- 
nificantly greater than the increase after orotracheal intubation. Many drugs, 
including narcotic analgesics, are effective in modifying cardiovascular re- 
sponses to orotracheal intubation. 
Objective: The effects of remifentanil and alfentanil on the cardiovascular 
responses to nasotracheal intubation were compared in healthy patients ched- 
uled to undergo surgery. 
Methods: This prospective, randomized, double-blind study was conducted 
at the Department of Anesthesiology and Reanimation, Faculty of Medicine, 
Dicle University, Diyarbakir, Turkey. Patients aged 16 to 65 years scheduled 
to undergo elective maxillofacial surgery and who were American Society of 
Anesthesiologists status I or II were randomly assigned to receive remifentanil 
1 IJg/kg in 10 mL saline over 30 seconds followed by an infusion of 0.5 IJg/kg • min, 
or alfentanil 10 pg/kg in 10 mL saline over 30 seconds followed by an infusion 
of saline. Anesthesia was then induced with propofol, cisatracurium, and 1% 
isoflurane with 66% nitrous oxide in oxygen. Heart rate (HR) and systolic and 
diastolic arterial pressures (SAP and DAP, respectively) were measured nonin- 
vasively at 2 minutes before general anesthesia induction (baseline); 2minutes 
after induction; and 1, 3, and 5 minutes after nasotracheal intubation. Patients 
were monitored for cardiac changes using electrocardiography. 
Results: Forty consecutive patients were enrolled in the study. Twenty 
patients (11 males, 9 females; mean [SD] age, 27.7 [12.6] years) received remifen- 
tanil, and 20 patients (12 males, 8 females; mean [SD] age, 31.5 [17.2] years) re- 
ceived alfentanil. Two minutes after anesthesia nduction, mean (SD) arterial pres- 
sures decreased significantly from baseline in the remifentanil group (changes, 
22 [8]/11 [6] mm Hg) and the alfentanil group (changes, 10 [9]/12 [8] mm Hg) 
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(both, P < 0.05). Changes in SAP and DAP followed a similar pattern in both groups, 
but SAP was significantly lower in the remifentanil group compared with that in 
the alfentanil group throughout the study period (all, P < 0.05). After 1 minute of 
intubation, DAP was significantly lower in the remifentanil group compared with 
that in the alfentanil group (66 [9] mm Hg vs 73 [20] mm Hg; P < 0.05). Compared 
with baseline, HR was decreased significantly in both groups throughout the study 
(all, P < 0.05). Except SAP in the alfentanil group, SAP, DAP, and HR were increased 
1 minute after intubation compared with preintubation values. However, SAP, DAP, 
and HR remained significantly lower compared with baseline values throughout 
the study period in both groups (all, P < 0.05) except DAP at 1 minute after intuba- 
tion in the alfentanil group. Five patients in the remifentanil group and 2 patients 
in the alfentanil group required treatment of hypotension. None of the patients in 
either group required treatment of bradycardia. 
Conclusions: In this study in healthy surgical patients aged 16 to 65 years, 
remifentanil 1 IJg/kg given over 30 seconds, followed by a remifentanil nfusion 
of 0.5 IJg/kg • min, was similarly effective compared with alfentanil 10 IJg/kg in 
attenuating the pressor esponse to nasotracheal intubation, but the incidence 
of hypotension in patients administered remifentanil was high. (Curr Ther Res 
Clin Exp. 2005;66:385-393) Copyright © 2005 Excerpta Medica, Inc. 
Key words: remifentanil, alfentanil, cardiovascular responses, nasotracheal 
intubation. 
INTRODUCTION 
Stimulation of the upper respiratory tract during tracheal intubation while a 
patient is under general anesthesia ctivates the sympathoadrenal system and 
in some cases results in hypertension, tachycardia, and an increase in intracra- 
nial pressure. 1-3 Many drugs, including narcotic analgesics, are effective in mod- 
ifying these cardiovascular responses. 4,5 
Nasotracheal intubation is often necessary in patients undergoing elective 
or emergency maxillofacial surgery. Previous studies 6,7 have suggested that the 
increase in blood pressure after this procedure is significantly greater com- 
pared with the increase after orotracheal intubation. Nasotracheal intubation is 
typically carried out in 3 stages. First, the tracheal tube is advanced through the 
nose and into the pharynx. Direct laryngoscopy is then used to identify the 
vocal cords. Finally, the tube is passed through the glottis and into the trachea. 
It is possible that stimulation of the nose and nasopharynx, which does not 
occur during orotracheal intubation, is responsible for the greater hypertensive 
response to nasotracheal intubation. 
Thompson et al 5 and Hall et al a assessed the effects of remifentanil on the 
cardiovascular response to orotracheal intubation in a randomized, double-blind 
study. Patients received a 1-1Jg/kg IV bolus dose of remifentanil over 30 seconds, 
followed by an infusion of 0.5 IJg/kg • min before the induction of anesthesia. 
Remifentanil effectively attenuated the pressor esponse to intubation. 
386 
G. Olmez et ol. 
Bolus doses of alfentanil 10 to 15 pg/kg have been shown to be effective in mod- 
ifying the cardiovascular response to intubation. 4,9 Specifically, narcotic analgesics 
prevent the occurrence and transmission of noxious timuli, and the reduction of 
stress-hormone release, thus attenuating the cardiovascular response to noxious 
stimuli related to intubation in general anesthesia nduction. High doses of alien- 
tanil (<45 pg/kg) have been associated with bradycardia and hypotension. 9 
Two studies of the relative potency of remifentanil and alfentanil are avail- 
able in the literature, l°,n In a pharmacokinetic model, Egan et al 1° found that 
remifentanil had 20- to 30-fold greater potency compared with alfentanil in 
healthy adult male volunteers, and that remifentanil and alfentanil were shown 
to have similar steady-state volumes of distribution; however, remifentanil had 
substantially greater central clearance. Hoke et a111 found that remifentanil was 
7.7- to 8.5-fold more potent compared with alfentanil in anesthetized dogs. 
Remifentanil was rapidly eliminated, with a tu2 of 6 minutes compared with 
19 minutes with alfentanil. 
Previous tudies have compared the effectiveness of remifentanil and alfentanil 
in attenuating the cardiovascular response to orotracheal intubation. 12-14 Studies 
have shown that the effectiveness of a bolus dose of remifentanil 0.5 pg/kg • min, 
followed by an infusion of 0.1 pg/kg, min, was similar to that of a 10-pg/kg bolus of 
alfentanil n controlling the cardiovascular response to orotracheal intubation in 
treated hypertensive patients 12 and elderly patients. 13Salihoglu et a114 found that 
the effectiveness of a bolus dose of remifentanil 1 pg/kg • min, followed by an infu- 
sion of 0.5 pg/kg • min, was similar to that of a 10-pg/kg bolus of alfentanil n con- 
trolling the cardiovascular response to orotracheal intubation. 
A search of articles on PubMed (key terms: cardiovascular responses, nasotra- 
cheal intubation, and narcotic analgesics; years: 1965-2005) revealed no studies 
of the attenuation of the cardiovascular responses to nasotracheal intubation. 
The aim of the present study was to compare the effectiveness of remifentanil 
and alfentanil n modifying the cardiovascular responses to nasotracheal intu- 
bation in adults undergoing surgery. 
PATIENTS AND METHODS 
This prospective, randomized, double-blind study was conducted at the De- 
partment of Anesthesiology and Reanimation, Faculty of Medicine, Dicle Uni- 
versity, Diyarbakir, Turkey. 
Consecutive patients aged 16 to 65 years, classified as American Society of 
Anesthesiologists status I or II, scheduled to undergo elective maxillofacial sur- 
gery under general anesthesia, nd requiring nasotracheal intubation as a part 
of the anesthetic management were recruited for the study. The ethics commit- 
tee at the university approved the study protocol. Written informed consent 
was obtained from all patients (and/or parents for those aged <18 years). 
Patients with cardiovascular disease, morbid obesity, esophageal reflux, 
hemorrhagic diathesis, hypersensitivity to opioids, or a history of nasal obstruc- 
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tion, and those receiving vasoactive drugs (eg, phenylephrine, phedrine, 
cocaine, antihypertensive agents, [5-blockers, ~-mimetics) were excluded from 
the trial. Patients with anatomic variations that might make intubation difficult 
(eg, micrognathia, prognathism, large tongue, temporomandibular ankylosis) 
were also excluded. 
Using the sealed-envelope technique, patients were randomly assigned to 
receive remifentanil or alfentanil n a double-blind manner. 
Thirty minutes before the induction of anesthesia, 2 sprays of xylometazoline 
were applied to the mucosa of each nostril during inhalation. Routine monitor- 
ing was initiated; heart rate (HR.), indirect arterial pressure, and arterial oxygen 
saturation were recorded at predetermined intervals throughout the study. After 
a stabilization period of at least 5 minutes, baseline recordings were obtained 
and the patient was administered 100% oxygen. All patients then received a 
bolus of either emifentanil (1pg/kg in 10 mL of saline over 30 seconds) followed 
by a remifentanil infusion of 0.5 pg/kg • min, or a bolus of alfentanil (10 pg/kg 
in 10 mL of saline over 30 seconds) followed by a saline infusion. Immediately 
after administration f the study drugs, anesthesia was induced with propofol 
2.5 mg/kg, and cisatracurium 0.2 mg/kg was administered toproduce neuromus- 
cular block. Isofiurane (1%) and nitrous oxide (66%) in oxygen were used to 
maintain anesthesia. Three minutes after induction, neuromuscular block was 
confirmed with a nerve stimulator (TOF-Guard, Organon Teknika, Turnhout, 
Belgium), and nasotracheal intubation was performed. All intubations were car- 
ried out by direct laryngoscopy with a Macintosh laryngoscope; a Magill forceps 
was used, if necessary. The right nostril was selected for intubations; if resis- 
tance was encountered, the left nostril was used. Disposable, cuffed, Portex 
nasotracheal tubes (sizes, 7.5 mm for males and 6.5 mm for females) lubricated 
with Silkospray (Rusch Inc., Duluth, Georgia) were used in all patients. 
An anesthetist not involved in the study prepared all of the narcotics. A 
blinded investigator administered the study drugs. The drugs were packaged 
in identical vials by the anesthetist to maintain blinding of the investigator. 
Another investigator intubated all of the patients. HR and systolic and diastolic 
arterial pressure (SAP and DAP, respectively) were measured by another inves- 
tigator noninvasively at 5 time points: 2 minutes before induction (baseline); 
2 minutes after induction; and 1, 3, and 5 minutes after intubation. 
The study protocol called for the treatment of cardiovascular changes using 
standard therapy. Hypotension was defined as a decrease in SAP to 230% below 
the baseline value and was treated using the administration of bolus doses of 
ephedrine (2.5 mg). An increase in SAP to 230% above the baseline value was defined 
as hypertension, and an HR of 130 bpm was defined as tachycardia. Both conditions 
were treated using 0.5% increases in the inspired concentration f isofiurane. 
The intubation time was defined as the interval between the removal of the 
face mask and reconnection ofthe circle system to the nasotracheal tube after 
intubation had been completed. If intubation was not completed within 60 sec- 
onds, the patient was withdrawn from the trial. 
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Patients were monitored for bradycardia, tachycardia, rrhythmia, ST segment, 
and other cardiac changes during the study, using electrocardiography (ECG). 
Statistical Analysis 
Power analysis based on previous data 4 suggested that 20 patients per group 
would provide 80% power for detecting a between-group difference in cardio- 
vascular esponse of 15 mm Hg (cz = 0.05, [5 = 0.2). Statistical analysis was per- 
formed using SPSS version 10.0 (SPSS Inc., Chicago, Illinois). The results are 
expressed as mean (SD). The Mann-Whitney U test was used to compare the 
independent nonparametric samples of the 2 groups, and the Wilcoxon signed 
rank test was used to compare paired samples. A P value <0.05 was considered 
statistically significant. 
RESULTS 
Forty consecutive patients were recruited for the study. All patients were in- 
tubated within 60 seconds. Twenty patients (11 males, 9 females; mean [SD] 
age, 27.7 [12.6] years) were included in the remifentanil group, and 20 patients 
(12 males, 8 females; mean [SD] age, 31.5 [17.2] years) in the alfentanil group. The 
baseline demographic and clinical characteristics (Table I) and hemodynamic 
variables (Table II) were statistically similar between the 2 treatment groups. 
After anesthetic induction, mean (SD) SAP/DAP decreased significantly from 
baseline in the remifentanil and alfentanil groups (changes, 22 [8]/11 [6] mm Hg 
and 10 [9]/12 [8] mm Hg, respectively; P < 0.05). The changes in SAP and DAP 
followed a similar pattern, but SAP was significantly lower in the remifentanil 
Table I. Baseline demographic and clinical characteristics of the study 
population (N = 40).* 
Remifentanil Alfentanil 
Characteristic (n = 20) (n = 20) 
Age, mean (SD), y 27.7 (12.6) 31.5 (17.2) 
Sex 
Male 11 1 2 
Female 9 8 
Weight, mean (SD), kg 62.9 (8.4) 64.3 (5.5) 
Duration of successful intubation, 
mean (SD), s 29.4 (2.8) 29.5 (2.3) 
ASA status 
I 17 16 
II 3 4 
ASA = American Society of Anesthesiologists. 
*No significant between-group differences were found. 
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Table II. Systolic and diastolic arterial pressure (SAP and DAP, respectively) (mm Hg) 
and heart rate (HR) (bpm) throughout the study. Values are presented as 
mean (SD). 
2 Min Before 
Induction 2 Min After 1 Min After 3 Min After 5 Min After 
Parameter (Baseline) Induction Intubation Intubation Intubation 
Remifentanil 
(n = 20) 
SAP 115 (13) 93 (14) *t 96 (15) *t* 96 (14) *t* 98 (13) *t* 
DAP 74 (10) 63 (9)* 66 (9) *t* 66 (9)** 69 (7)** 
HR 91 (10) 75(16)* 81 (15)** 79(12)** 78(11)* 
Alfentanil 
(n = 20) 
SAP 118(14) 108(21)* 112 (22)* 108(17)* 108(16)* 
DAP 76 (9) 64 (7)* 73 (20)* 71 (9)* 70 (8)* 
HR 91 (13) 81 (9)* 87 (12)** 78 (7)** 77 (7)** 
*P < 0.05 versus baseline. 
tp < 0.05 versus alfentanil. 
*P < 0.05 versus 2 minutes after anesthesia induction. 
group compared with that in the alfentanil group throughout the study period 
(all, P< 0.05). Alter 1 minute of intubation, DAP was significantly ower in the remi- 
fentanil group compared with that in the alfentanil group (66 [9] vs 73 [20] mm Hg; 
P < 0.05). HR was decreased significantly from baseline in both groups throughout 
the study (all, P < 0.05). Except SAP in the alfentanil group, SAP, DAP, and HR 
were significantly increased 1minute after intubation compared with preintuba- 
tion (all, P < 0.05). However, SAP, DAP, and HR remained significantly ower than 
baseline values in both groups throughout the study period (all, P < 0.05) ex- 
cept DAP at 1 minute after intubation in the alfentanil group. 
Five patients in the remifentanil group and 2 patients in the alfentanil group 
required ephedrine for the treatment of hypotension. None of the patients in 
either group required treatment for bradycardia. No significant differences in 
the occurrence of bradycardia or hypotension were found between the 2 
groups. However, in the remifentanil group, 4 patients had transient bradycar- 
dia; none of the patients in the alfentanil group experienced this effect. In addi- 
tion, 3 patients in the remifentanil group and 4 in the alfentanil group had 
increased blood pressure after intubation. However, because the increases were 
~10 mm Hg, none of the patients were withdrawn from the study because of 
hypertension. No other adverse vents (eg, tachycardia, rrhythmias, ST-segment 
or other ECG changes) were observed uring the study. 
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DISCUSSION 
Cardiovascular responses to laryngoscopy and tracheal intubation are well 
documented. A number of methods can be used to modify these responses, 
including the administration of remifentanil and alfentanil. 4,5,12-14 Remifentanil 
is a structurally unique opioid agent. An ester bond renders it subject o rapid 
hydrolysis by nonspecific blood and tissue esterases; thus it has a short tl,2 .15 l 
The onset of action is rapid (1-2 minutes) and similar to that of alfentanil. 14
Therefore, remifentanil might be appropriate for the attenuation of the pressor 
responses to brief but noxious timuli. Some studies 12-14 have shown that remi- 
[entanil and alfentanil are similarly effective in reducing the cardiovascular re- 
sponses to laryngoscopy and orotracheal intubation. 
However, the cardiovascular disturbances produced by nasotracheal intuba- 
tion are greater than those attributable to orotracheal intubation. In a study 
comparing nasotracheal with orotracheal intubation, Smith and Grewal 7 found 
that the hypertensive response to nasotracheal intubation with the patient 
under general anesthesia was significantly greater and more sustained com- 
pared with that of orotracheal intubation. In that study, a narcotic analgesic was 
not used at the induction of anesthesia. Our literature search revealed no stud- 
ies of modifying cardiovascular responses, including by the administration of
either remifentanil or alfentanil, in otherwise healthy patients receiving naso- 
tracheal intubation. 
In the present study, the cardiovascular effects of remifentanil and alfentanil 
at the induction of anesthesia and nasotracheal intubation were similar. After 
the induction of anesthesia, rterial pressures decreased significantly, but re- 
mained within acceptable limits, in both groups. After nasotracheal intuba- 
tion, the arterial pressures increased significantly compared with values before 
intubation (except SAP at 1 minute in the alfentanil group) but remained signifi- 
cantly lower compared with baseline values at 5 minutes after intubation 
(except DAP at 1 minute after intubation in the alfentanil group). These findings 
suggest that the cardiovascular response is effectively suppressed with narcot- 
ic analgesics and that alfentanil and remifentanil are similarly effective. 
In the present study, none of the patients in either group required treatment 
for hypertension or tachycardia. Salihoglu et a114 investigated the effects of 
remifentanil, alfentanil, and [entanyl on the cardiovascular response to intuba- 
tion in morbidly obese patients in a placebo-controlled trial. Fifteen percent 
(3/20) of patients in the remifentanil group, 5% (1/20) in the alfentanil group, 
and 50% (10/20) in the control group required an increase in the inspired con- 
centration of isofiurane to treat hypertension. A similar study was conducted 
by Habib et a113 in elderly patients; 5% (1/20) of patients in the remifentanil 
group and 10% (2/20) in the alfentanil group received an increased inspired con- 
centration of isoflurane to treat hypertension. 
Smith and Grewal 7 found that the prevalence of tachycardia associated with 
nasotracheal intubation is significantly ess compared with that associated with 
orotracheal intubation during the first minute after intubation. They suggested 
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that the slower heart rate might be mediated by baroreceptor reflexes in re- 
sponse to a more rapid increase in arterial pressure during nasotracheal intuba- 
tion, or it might be the result of the influence of the nasocardiac reflex. 
In the present study, 4 patients in the remifentanil group experienced transient 
bradycardia, but none of them required treatment. Previous tudies 5~ have shown 
a high incidence of bradycardia and/or hypotension associated with remifentanil 
use in the absence of a vagolytic drug. Thompson et al 5 found that remifentanil was 
associated with bradycardia and/or hypotension i 50% (5/10) of patients com- 
pared with 10% (1/10) of patients who received remifentanil and glycopyrrolate. 
An exaggerated hypertensive r sponse to nasotracheal intubation, although 
probably of little consequence in young, fit individuals, might represent a seri- 
ous risk to patients with cardiovascular disease or those in the intensive care 
unit who are subject o cardiovascular instability. Induction of anesthesia with 
remifentanil or alfentanil may depress the cardiovascular response in such pa- 
tients. Drug-induced hypotension might also be dangerous to these patient 
populations. Studies undertaken i hypertensive 12 and elderly 13 patients have 
shown that the use of remifentanil and alfentanil at the induction of anesthesia 
and during orotracheal intubation was effective in pressor response attenua- 
tion. However, the incidence of hypotension confirms that both drugs should be 
used with caution in those patient populations. 
In the present study, the incidence of hypotension was higher and the 
decrease in SAP was greater in the remifentanil group. Thompson et al 5 found 
that pretreatment with a vagolytic agent might be required if the incidence of 
bradycardia or hypotension is to be minimized. It is possible that a lower dose 
of remifentanil may be effective while reducing the risk for hypotension. 
This study has several limitations. The patients recruited were not at risk for 
cardiovascular dverse vents. Also, no outcome data were collected. 
CONCLUSION 
In this study in healthy surgical patients aged 16 to 65 years, remifentanil 1 IJg/kg 
given over 30 seconds, followed by a remifentanil infusion of 0.5 IJg/kg • min, was 
similarly effective compared with alfentanil 10 IJg/kg in attenuating the pressor 
response to nasotracheal intubation, but the incidence of hypotension i  patients 
administered remifentanil was high. 
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